Diagnostic imaging equipment allows physicians to view the inside of the human body to help them find any indications of a health condition. The main types of diagnostic imaging equipment are x-ray systems devices and equipment, ultrasound systems devices and equipment, computed tomography (CT) scanners devices and equipment, magnetic resonance imaging systems devices and equipment, cardiovascular monitoring, diagnostic devices and equipment, and nuclear imaging devices, and equipment. Nuclear imaging device and equipment uses a special gamma camera and single-photon emission-computed tomography (SPECT) imaging techniques. The gamma camera records the energy emissions from the radiotracer in the body and converts them into an image. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The diagnostic imaging equipment market research report is one of a series of new reports from The Business Research Company that provides diagnostic imaging equipment market statistics, including diagnostic imaging equipment industry global market size, regional shares, competitors with a diagnostic imaging equipment market share, detailed diagnostic imaging equipment market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic imaging equipment industry. This diagnostic imaging equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global diagnostic imaging equipment market grew from $48.71 billion in 2022 to $51.08 billion in 2023 at a compound annual growth rate (CAGR) of 4.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diagnostic imaging equipment market is expected to grow to $59.1 billion in 2027 at a CAGR of 3.7%. Portable diagnostic equipment is expected to be a fast-growing segment, and competitors are focusing on developing new and innovative portable equipment during the forecast period. Owing to their ease of use and point-of-care applications, their adoption rates are steadily increasing not only for emergency and intensive care units in hospitals, but also as a part of home care organizations. There is also a growing need for portable devices in the emergency care units for easy and quick usage, faster interventions for acute events, and better monitoring. Some of the well-known products include Samsung Electronics’ 32-SLICE CT scanner, Brain Biosciences’ CERPET portable PET scanner, Siemens Healthcare’s Mobilett mira max portable X-ray systems, and Sonosite’s MicroMaxx portable ultrasound system. Major companies in the diagnostic imaging equipment market include Siemens AG, Koninklijke Philips N.V., Fujifilm Corporation, Varian Medical Systems, General Electric Company, Elekta, Carestream Health, Inc., Exact Sciences, Hologic, Inc., and Stryker Corporation. Western Europe was the largest region in the global diagnostic imaging equipment market in 2022. North America was the second largest region in the global diagnostic imaging equipment market. Africa. was the smallest region in the global diagnostic imaging equipment market. The regions covered in the diagnostic imaging equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diagnostic imaging equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The diagnostic imaging equipment market consists of sales of breast imaging devices, brain, neuroimaging devices, 3d medical imaging devices, and other devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global diagnostic imaging equipment market is segmented - 1) By Type: X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Diagnostic and monitoring ophthalmic devices and equipment are used for the diagnosis and monitoring of diseases related to the retina and cornea by measuring affix lenses and refractive errors. These devices also help identify the intraocular lenses (IOLs) and analyze the visual field. The main product types in the diagnostic and monitoring ophthalmic devices and equipment are optical coherence tomographers, ophthalmic ultrasound imaging systems, fundus cameras, ophthalmoscopes, keratometers, specular microscopes., tonometers, slit lamps, retinoscopes, and others (dioptometers, optotype projector, perimeters, and biometers, pachymeters, autorefractors/phoropters, corneal topographers, wavefront aberrometer, wavefront aberrometer). Fundus cameras are used for diagnosing and monitoring and are used in imaging of a rear eye. These are used in various applications such as retinal evaluation, glaucoma detection, and monitoring, surgical evaluation, general examination, intraoperative devices, and refraction equipment. The diagnostic and monitoring ophthalmic devices are used in hospitals, clinics, diagnostic laboratories, and research centres. The diagnostic and monitoring ophthalmic devices and equipment market research report is one of a series of new reports from The Business Research Company that provides diagnostic and monitoring ophthalmic devices and equipment market statistics, including diagnostic and monitoring ophthalmic devices and equipment industry global market size, regional shares, competitors with a diagnostic and monitoring ophthalmic devices and equipment market share, detailed diagnostic and monitoring ophthalmic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic and monitoring ophthalmic devices and equipment industry. This diagnostic and monitoring ophthalmic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global diagnostic and monitoring ophthalmic devices and equipment market size will grow from $2.5 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diagnostic and monitoring ophthalmic devices and equipment market size is expected to grow from $3.6 billion in 2027 at a CAGR of 7.3%. The increasing prevalence of eye diseases is expected to drive the demand for diagnostic and monitoring equipment in the ophthalmic devices industry. The rise in surgeries associated with eye disorders like cataracts, diabetic retinopathy, and glaucoma has increased the demand for diagnostic and monitoring ophthalmic devices. According to a study, 4 out of 10 people have been found to have cataract disease in their early stages of life. The absolute number of cataract blind in 2020 would be 8.25 million, due to a substantial increase in the population above 50 years in India. Lack of awareness about eye diseases mostly in developing and underdeveloped nations is expected to hinder the growth of the diagnostic and monitoring ophthalmic devices and equipment market. BLack of awareness of eye disorders results in fewer patients going for a routine eye check-up or diagnosis of the disorder, impacting the demand for diagnostic and monitoring ophthalmic equipment. According to a study conducted by the vision impact institute, 42% of drivers in India have vision-related problems leading to 59% of road accidents. According to WHO, 550 million people in the country need vision correction and to achieve this, companies should increase awareness & provide vision care to people living in rural and semi-urban areas. Advanced eye care medical devices equipped with artificial intelligence (AI) and machine learning (ML) are the new trends in the ophthalmic diagnostic and monitoring equipment market. AI and ML-equipped medical devices can not only quickly interpret the eyes of the patient with better accuracy but also recommend a suitable treatment for the patient. Deepmind, a subsidiary of Alphabet Inc. has developed an AI-based system that is capable of analyzing 3D retinal OCT scans for detecting severe diseases like glaucoma, retinopathy, macular degeneration, and 50 different types of eye diseases at their early stage. The increased regulatory compliance norms by the Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have impacted the market making the approval/regulation process for diagnostic and monitoring ophthalmic devices strenuous. Complex and tedious premarket and postmarket submissions by FDA may increase the product release time and incur heavy costs on device development. The MHRA considers a medical device to be any equipment used for the diagnosis or treatment of disease, or for monitoring patients and recommends Yellow card reporting for ophthalmic devices and products as well. All the adverse events and the causes for any untoward incidents must be reported in the yellow card, allowing the equipment to be monitored thoroughly for enhanced patient safety. In July 2020, Topcon, a company manufacturing optical equipment based in Japan acquired Elektron Eye Technology for an undisclosed amount. This acquisition includes the products of the Henson line of perimetry such as Henson 9000 and 7000 that perform suprathreshold glaucoma screening and the product manufacturing will remain in the UK. Elektron Eye Technology is a company operating in the diagnostic and monitoring of ophthalmic devices based in the UK. Major players in the diagnostic and monitoring ophthalmic devices and equipment market are Carl Zeiss Meditec, Alcon, Bausch + Lomb, Haag-Streit, Topcon Corporation, Nidek Co. Ltd., Abbott Medical Optics, Johnson and Johnson Vision Care, Essilor International S.A, and Ziemer Ophthalmic Systems AG. North America was the largest region in the global diagnostic and monitoring ophthalmic devices and equipment market in 2022. Asia-Pacific was the second largest market in diagnostic and monitoring ophthalmic devices and equipment market. The regions covered in the global diagnostic and monitoring ophthalmic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diagnostic and monitoring ophthalmic devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The Diagnostic and monitoring ophthalmic devices and equipment market consist of sales of ultrasound imaging systems ophthalmoscopes, corneal topographers, specular microscopes, slit lamps, fundus cameras, anomaloscope, haploscope, ophthalmic lens gauge, stereopsis measuring Instrument, retinoscopes, stereoscope, and others that are used for diagnosis and monitoring of ophthalmic diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global diagnostic and monitoring ophthalmic devices and equipment market is segmented - 1) By Product Type: Optical coherence tomographers, Ophthalmic ultrasound imaging systems, Fundus cameras, Ophthalmoscopes, Keratometers, Specular microscopes., Tonometers, Slit Lamps, Retinoscopes, Others(Dioptometers, Optotype projector, Perimeters, and Biometers,Pachymeters,Autorefractors/phoropters,Corneal topographers,Wavefront abberometers,Wavefront abberometers) 2) By End User: Hospitals, Clinics, Diagnostic Laboratories, Research Centers 3) By Application: Retinal evaluation, Glaucoma detection and monitoring, Surgical evaluation, General examine, Intraoperative devices, Refraction equipment

Microbiology diagnostics devices and equipment are a broad category covering all kinds of items used in microbiology laboratories and used to diagnose infectious diseases by examining pathogens. These devices and equipment included microscopes, slides, test tubes, Petri dishes, growth media (liquid and solid), inoculation loops, pipettes, and tips, incubators, autoclaves, and laminar flow hoods. Some pieces of equipment are permanent, like microscopes and hoods, while others are not, like pipette tips. The main types of microbiology diagnostic devices and equipment are laboratory instruments, and microbiology analyzers. Laboratory instruments are types of instruments such as incubators, gram stainers, bacterial colony counters, petri dish fillers, and automated culture systems that are needed for operations in the laboratories. The micro-biology analyzers involved are microbiology diagnostics instruments and microscopes. The reagents are pathogen-specific kits, and general reagents. The end-users involved are hospitals, diagnostic centres, customer lab service providers, academic institutes, and research institutes. The microbiology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides microbiology diagnostics devices and equipment market statistics, including microbiology diagnostics devices and equipment industry global market size, regional shares, competitors with a microbiology diagnostics devices and equipment market share, detailed microbiology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the microbiology diagnostics devices and equipment industry. This microbiology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global microbiology diagnostic devices and equipment market size will grow from $3.94 billion in 2022 to $4.43 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiology diagnostic devices and equipment market size is expected to grow from $6.35 billion in 2027 at a CAGR of 9.4%. Increasing funding of public and private investments in medical devices is driving the growth of the microbiology diagnostic devices market. Increasing Investments indicate the rising confidence of various private and public players on microbiology diagnostic devices, thereby indicating a progressive increase and stimulating growth. For instance, according to MedTech news, a publisher of new related to medical technology, private equity industry invested $111.8 B (c.$ 151 B) in healthTech industry. Furthermore, globally 96 deals valued at $40.8 billion were completed in medTech vertical. The increasing investments in digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, and customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Unfavourable regulatory scenarios are major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug, and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous, and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as the capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration, and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next-Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to their cost effectiveness, sensitivity to detect low-frequency variants, and comprehensive genomic coverage. Next-Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with the ability to sequence hundreds to thousands of genes or gene regions and the capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, an NGS service that will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next-generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. On May 26th, 2022, The IVD Regulation seeks to ensure a high level of public health and patient safety taking into account scientific progress, and smooth operation of the single market for these products. These changes by the EU legislation aid in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In April 2022, DCN Dx, a US-based manufacturer and developer of point-of-use tests, acquired Biomed Diagnostics for an undisclosed amount. The acquisition would expand DCN Dx’s footprint in the vertical of point-of-use testing and sampling markets for both humans and animals.Biomed Diagnostics is a US-based microbiological testing company. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, and Charles River Laboratories International Inc. North America was the largest region in the microbiology diagnostics devices and equipment market in 2022. Asia-Pacific was the second largest region in the global microbiology diagnostic devices and equipment market. The regions covered in the global microbiology diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the microbiology diagnostics devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The microbiology diagnostic devices and equipment consists of sales of instruments such as incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen-specific kits, and general reagents for microbiology diagnostic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents

The oncology molecular diagnostics refers to procedure for diagnosing cancers and related services. Molecular diagnostics are tests that diagnose genetic information, proteins, or related molecules and provide health or disease information. The main products in oncology molecular diagnostics are instruments, reagents, and others. The oncology molecular diagnostics instruments are used for diagnosing cancer.. The various technologies involved are polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermic nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectroscopy, transcription-mediated amplification (TMA), and others. These are used by variousend-users,s such as hospitals, diagnostic centres, academic and research institutes, and others. The oncology molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology molecular diagnostics market statistics, including oncology molecular diagnostics industry global market size, regional shares, competitors with a oncology molecular diagnostics market share, detailed oncology molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the oncology molecular diagnostics industry. This oncology molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oncology molecular diagnostics market grew from $3.66 billion in 2022 to $4.19 billion in 2023 at a compound annual growth rate (CAGR) of 14.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology molecular diagnostics market is expected to grow from $7.11 billion in 2027 at a CAGR of 14.2%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oncology molecular diagnostics market. According to the American Cancer Society, there were 1.8 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the oncology molecular diagnostic market over the coming years. The high cost of molecular diagnostic tests is a key factor hampering the growth of the oncology molecular diagnostics market. The cost of molecular diagnostic testing is comparatively higher in cancer care and it also depends on the type of therapy. For example, the cost of the molecular diagnostic test for non-small cell lung cancer monotherapy costs about $10,000 to $20,000 per month, and these costs are expected to increase in combination therapy. Therefore, the high cost of molecular diagnostic tests is expected to hamper the growth of the oncology molecular diagnostics market. The advanced technology in genomics is a key trend in the oncology molecular diagnostics market. Advancements in cancer genome sequencing technology, computational analysis, tumor models, and innovation of modern cancer research methods promote early detection of cancer and its mutation. For instance, Roche Molecular Systems, Inc., a US-based company, developed Cobas EGFR Mutation Test for non-small cell lung cancer patients. This test is a real-time test that detects 42 mutations of the epidermal growth factor receptor (EGFR) gene, along with the resistant mutation of cancer. In June 2020, FDA approved Cobas EGFR Mutation Test. In HealthCare Global Enterprises Limited, an India-based oncology care provider acquired Oncology hospital labs and clinical trial business from Strand Lifesciences. The acquisition HCG would enhance its in-house diagnostic and research capabilities and drive higher awareness and adoption of cancer diagnostics. Strand Lifesciences is a India-based oncology and technology company. Major players in the oncology molecular diagnostics market are Abbott Diagnostics, Becton Dickinson, Cepheid, Danaher Corporation, Beckman Coulter, Leica Biosystems, Gen-Probe (Hologic), Qiagen N.V., Roche Diagnostics, and Siemens Healthcare. North America was the largest region in the oncology molecular diagnostics market in 2022. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the global oncology molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology molecular diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology molecular diagnostics market includes revenues earned by oncology molecular diagnostics tools and kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology molecular diagnostics market is segmented - 1) By Product: Instruments, Reagents, Other Products 2) By Technology: Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies 3) By End User: Hospitals, Diagnostic Centers, Academic & Research Institutes, Other End Users

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

Care management solutions are a suite of services that patients can used to manage their chronic health conditions. They are used to provide a complete set of services and activities designed to assist people with chronic or complicated medical illnesses. The main types of components in care management solutions are software and services. The services refer to a comprehensive suite of services and activities that help patients with chronic or complex conditions manage their health. The care management solutions are delivered via on-premises and cloud-based methods that are used in several applications such as disease management, case management, and utilization management. It is employed in hospitals and clinics, accountable care organizations (ACOs), health insurance providers, and other end users. The care management solutions market research report is one of a series of new reports from The Business Research Company that provides care management solutions market statistics, including care management solutions industry global market size, regional shares, competitors with a care management solutions market share, detailed care management solutions market segments, market trends and opportunities, and any further data you may need to thrive in the care management solutions industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global care management solutions market size grew from $14.14 billion in 2022 to $16.56 billion in 2023 at a compound annual growth rate (CAGR) of 17.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The care management solutions market size is expected to grow to $29.47 billion in 2027 at a CAGR of 15.5%. The increase in investment in digital healthcare is expected to propel the growth of the care management solutions market going forward. Digital healthcare prevents disease and lowers healthcare costs while helping patients monitor and manage chronic conditions. It can also tailor medicine for individual patients. A digital healthcare solution would allow users to share and receive files online via desktops, laptops, and mobile devices. For instance, according to the Healthcare Information and Management Systems Society, a US-based not-for-profit healthcare organization, in 2021, the financing for digital communication technology grew by 72% during the COVID-19 outbreak, and telemedicine alone received $4.3 billion in financing in 2020. The total amount invested in digital health has hit an all-time high of $26.5 billion. Therefore, the increasing investment in digital healthcare is driving the demand for the care management solutions market. Technological advancement is a key trend gaining popularity in the care management solution market. Major companies operating in the care management solutions sector are focused on developing new technological solutions to strengthen their position in the market. For instance, in October 2020, VirtualHealth, a US-based comprehensive care management platform, introduce HELIOS Essentials. HELIOS Essentials provides unprecedented configuration and potent AI-powered automations for specialist care providers and mid-size healthcare companies. It dismisses data silos, streamlines operations, uses less IT resources, and enables value-based, whole-person care. This launch represents another step forward for the company and the care management solutions market. In January 2021, Royal Philips, a US-based health technology company, acquired Capsule Technologies, Inc. for a deal amount of $635 million. Through this acquisition, Philips would expand its patient care management offering and look forward to participating strengths, adding a vendor-neutral medical device combination that further unlocks the ability of medical device data to improve patient monitoring and management. Capsule Technologies is a US-based company that provides medical device integration, clinical surveillance, and patient monitoring for hospitals. Major players in the care management solutions market are Cerner Corporation, International Business Machines Corporation, Koninklijke Philips N.V., ZeOmega Infotech Private Limited, i2i Population Health, EPIC Systems Inc., Salesforce Inc., Pegasystems Inc., Mediware Information Systems, Allscripts Healthcare Solutions Inc., EXL Service Holdings, Exlservice Holdings Inc., Zeomega Inc., Health Catalyst Inc., Conduent Inc., Envolve Health, Trizetto Corporation, Healthsmart Holdings Inc., and Axispoint Health. North America was the largest region in the care management solutions market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the care management solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the care management solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The care management solutions market includes revenues earned by entities by providing case and disease management and value-based services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global care management solutions market is segmented - 1) By Component: Software, Services 2) By Delivery Mode: On-premise, Cloud-based 3) By Application: Disease Management, Case Management, Utilization Management 4) By End User: Hospitals And Clinics, Accountable Care Organizations (ACOs), Health Insurance Providers, Other End-Users

Point-of-care (POC) molecular diagnostics refers to tests that detect the presence of specific nucleic acids in a clinical specimen, such as feces, saliva, urine, blood, and tissue. This molecular diagnostic is based on seeing targeted portions of microbial genetic material, DNA or RNA. It is utilized by the healthcare sector to detect emergency usage authorization to diagnose diseases. Point-of-care (POC) molecular diagnostic is used to detection of disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).  The main product and services of point-of-care molecular diagnostics are assays and kits, instruments and analyzers and software and services. Assays and kits refer to the equipment which is used in carrying out analyses such as studying disease pathways. Assays and kits were widely used for detecting rapid and accurate diagnosing and monitoring various diseases. Reverse transcription-polymerase chain reaction (RT-PCR), in situ-hybridization and sequencing are the technologies used in point-of-care molecular diagnostics that are used for diagnosis of diseases such as respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis and hematology. Decentralized labs, hospitals, home care, and assisted living healthcare facilities use point of care molecular diagnostics. The point-of-care molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global point-of-care molecular diagnostics market size grew from $2.8 billion in 2022 to $3.14 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The point-of-care molecular diagnostics market size is expected to grow to $4.98 billion in 2027 at a CAGR of 12.2%. The rapid growth in the increasing occurrence of infectious and respiratory diseases is expected to significantly contribute to the growth of the point-of-care molecular diagnostics market. Respiratory infections, such as viruses or bacteria, are caused by microorganisms that influence the respiratory system. These microbes can be transferred through coughing, sneezing, or direct touch. The severity of the respiratory medications includes a variety of inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostic to cure the patient. For instance, in May 2020, an annual Report on MCCD (Medical Certification of Cause of Death) 2020 shows that respiratory system diseases are the second most common cause of death, accounting for 10% of the total medically certified causes of death (88.7%). Furthermore, between 2019 and 2020, the number of deaths caused by respiratory disorders increased from 152,311 to 181,160. Therefore, the rapid occurrence of infectious and respiratory diseases and death will drive the point-of-care-molecular diagnostics market. Technological innovation is a key trend gaining popularity in the point-of-care molecular diagnostics market. Major companies operating in the point-of-care molecular diagnostics market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation point-of-care molecular diagnostics technologies solutions and related services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, and others to implement on POC devices with features of accelerating analysis times and lowering costs. For instance, in March 2020, Abbott Laboratories, a US-based medical device company, launched the molecular point-of-care test available for detecting new COVID-19 (COVID-19). According to the company, the device shows positive results in five minutes and negative in 13 minutes. This test will run on the ID NOW™ platform with isothermal nucleic acid amplification technology that generates molecular results in minutes. In February 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents, consumables, and software services firm acquired Mesa Biotech for an undisclosed amount. With this acquisition, Thermo Fisher Scientific will expand into molecular diagnostics at the point-of-care by bringing much-needed diagnostics to market on a larger scale. Mesa Biotech is a US-based point-of-care molecular diagnostic company. Major players in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, Qiagen Gmbh, Biocartis NV, Nova Biomedical, Thermo Fisher Scientific, Dickinson and Company, Mesa Biotech Inc., OraSure Technologies Inc., Bio-Rad Laboratories Inc., Sysmex, Siemens Healthineers, Bayer HealthCare Pharmaceuticals LLC, Alere Inc., Lucira Health Inc., Cue Health, OpGen Inc., Binx Health Inc., Molbio Diagnostics Pct Ltd., Genomadix, Visby Medical, QuikPath PTE Ltd., QuantuMDx Group Ltd and Sekisui Medical Co Ltd. North America was the largest region in the point-of-care molecular diagnostics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global point of care molecular diagnostics market is segmented - 1) By Product And Service: Assays And Kits, Instruments And Analyzers, Software And Services 2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR), In Situ Hybridization, Sequencing 3) By Application: Respiratory Diseases, Hospital Acquired Infections (HAIs), Cancer/Oncology, Hepatitis, Hematology 4) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities

The diagnostic devices (or) equipment market consists of sales of diagnostic equipment and related services by entities (organizations, sole traders, and partnerships) that are used to identify the nature or cause of a certain phenomenon, usually related to a medical condition. Some of the devices include magnetic resonance imaging apparatuses, temperature sensors or pacemakers. The main types of diagnostic devices or equipment are x-rayed systems, ultrasound systems, computed tomography (CT) scanners, magnetic resonance imaging systems, cardiovascular monitoring and diagnostic devices, and nuclear imaging devices. X-rays refer to a type of electromagnetic radiation, just like visible light. The mobility is stationary and mobile and is used in hospitals and diagnostic imaging centers. The global diagnostic equipment market size is expected to grow from $43.81 billion in 2021 to $47.74 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The global diagnostic equipment market size is expected to grow to $59.46 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. An increase in the geriatric population is expected to propel the growth of the diagnostic devices market going forward. Older people are likely to suffer from diseases such as diabetes, cancer, and arthritis, among others, which would increase the demand for diagnostic devices. For instance, in 2020, according to the United Nations, a US-based intergovernmental organization, there are approximately 727 million persons are aged 65 years and above worldwide, and expected to reach approximately 1.5 billion persons by 2050. Therefore, the increase in the geriatric population is driving the growth of the diagnostic devices market.  The emergence of routine diagnostic kits is a key trend gaining popularity in the diagnostic devices market. Companies operating in the market are focusing on developing diagnostic kits to gain market coverage. For instance, in March 2022, Mylab Discovery Solutions, an India-based healthcare company, is set to launch an entire range of routine diagnostic kits and devices in conventional and point-of-care formats. Immunology, Biochemistry, and Haematology are the three main market sub-segments represented by the devices and kits included in them.  In July 2021, DiaSorin S.p.A., an Italy-based biotechnology company, acquired Luminex Corporation for a deal amount of $1.8 billion. Through the acquisition, DiaSorin would gain access to Luminex’s multiplexing technology and a portfolio that would strengthen its existing offering while expanding the group's presence in the United States. Further, this agreement would give the life science sector access to Luminex's applications, promoting academic and scientific research, improving collaboration with biopharma businesses, and boosting access to clinical multiplexing assays for upcoming Value-Based Care initiatives. Luminex Corporation is a US-based biotechnology company that manufactures medical diagnostic devices. Major players in the diagnostic equipment market include Philips Healthcare, Hitachi Medical Systems, Fujifilm Holdings, Siemens Healthcare, and GE Healthcare. The regions covered in global diagnostic equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic devices or equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global diagnostic equipment market is segmented - 1) By Type: X-Ray Systems, Ultrasound Systems, Computed Tomography (CT) Scanners, Magnetic Resonance Imaging Systems, Cardiovascular Monitoring and Diagnostic Devices, and Nuclear Imaging Device 2) By Mobility: Stationary, Mobile 3) By End User: Hospitals, Diagnostic imaging centres